SPSanthosh Penta

Santhosh Penta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Santhosh Penta has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design, Synthesis, ADME/Tox, and Molecular Modeling of Novel Bis ‐1,2,3‐triazoles‐Linked Quinoxalines as Significant Anticancer Agents

    by Naveen Kumar Sureddy, Santhosh Penta, Tungabidya Maharana, Lavanya Lahari Pannuri, Hrutik Madhavrao Jadhav, Srinivasa Rao Papineni

    In order to target lung and breast cancer therapy, a novel series of quinoxaline‐substituted‐ bis ‐1,2,3‐triazoles 6a–6l was devised and synthesized by click reaction. All of the synthesized compounds' structures were thoroughly determined using IR, HRMS, and NMR ( 1 H/ 13 C) investigations. With IC 50 values of 11.20 ± 2.60, 3.12 ± 2.80, 10.37 ± 1.26, 4.10 ± 0.90, and 3.04 ± 3.13 µM, respectively, five compounds— 6b , 6e , 6f , 6j , and 6l —showed encouraging anticancer activity on the A549 cell line. These compounds were all more effective than doxorubicin (DXN), which had an IC 50 of 3.26 ± 0.87 µM. The representative compounds in this series, 6j and 6l , exhibited higher anticancer activity than other compounds and DXN control against the lung (H358) cell line with IC 50 of 5.71 ± 3.20 and 6.29 ± 0.80 µM. Studies into the physicochemical characteristics of novel compounds, such as 6e and 6j , found problems with Lipinski violations and bound GI absorption, despite their superior ADME/Tox characteristics, which can be used to design new anticancer medicines. In order to better understand the mechanism and binding modalities of these ligands 6c , 6e , and 6j in the EGFR‐binding pocket of lung cancer as an alternative target (PDB codes: 2ITO, 1X2R), molecular docking studies were additionally carried out. Through their distinct chemical characteristics, the expertise provided may eventually result in the creation of new, useful anticancer drugs to combat the increasing issue of drug resistance.

  • Design, synthesis and molecular docking studies of isoquinoline based 1,2,3-triazolyl chalcones as potential anti-cancer agents

    by Murali Boddupalli, Santhosh Penta, Lavanya Lahari Pannuri, Hrutik Madhavrao Jadhav, Haribabu T, B.V. Subbareddy, Sunil Misra


  • Design, Synthesis, and In‐Silico Molecular Docking Studies of 1,2,3‐Triazole‐Bearing Oxepinopyridine Derivatives as Potent Anticancer Agents

    by Naveen Kumar Sureddy, Santhosh Penta, T. Maharana, Lavanya Lahari Pannuri, Hrutik Madhavrao Jadhav, Srinivas Rao Papineni

    A new series of oxepine–pyridine analogues (6a–k) incorporating 1,2,3‐triazole moieties was synthesized and evaluated for anticancer potential. The compounds were characterized using 1 H NMR, 13 HC NMR, mass spectrometry, and IR spectroscopy. In vitro cytotoxicity screening against HCT‐116, HCT‐15, HeLa, and MCF‐7 cell lines revealed promising results. Compounds 6b and 6g displayed strong inhibitory activity against HCT‐116 cells with IC 50 values of 5.9 ± 0.1 and 4.6 ± 0.2 µM, respectively. Several other analogues showed moderate to excellent activity, particularly against HeLa cells. Compounds 6d and 6e exhibited the highest efficacy against MCF‐7 cells, with IC 50 values of 12.6 ± 0.2 and 7.2 ± 0.2 µM, respectively. Molecular docking studies highlighted compound 6e as the most promising, forming extensive amino acid interactions with the active site of the STAT3B (1BG1) receptor, achieving a docking score of –10.85 kcal/mol. Furthermore, physicochemical and ADMET properties were predicted using Swiss ADME and ADMET lab 2.0, supporting favourable drug‐like characteristics. Overall, the study suggests that dihydrooxepine scaffolds with triazole incorporation offer an excellent structural framework for the development of potent anticancer agents.

  • New Quinazolinone‐Tethered 1,2,3‐Triazoles aSs Potent Antimicrobial Agents: Design, Synthesis, Biological Evaluation and in silico Docking Study

    by Jeevan Lal Patel, Naveen Kumar Sureddy, Raju Chedupaka, Venkatesham Papisetti, S. P. Mahapatra, Santhosh Penta

    Novel 1,2,3‐triazole acetamide linked quinazolinone derivatives were synthesized via click reaction, by reacting of 3‐methyl‐2‐(prop‐2‐yn‐1‐ylthio)quinazolin‐4(3 H )‐one with various aryl azides as prominent fungal pathogen Candida albicans interactions. The prepared triazole compounds were characterized using mass spectrometry, 1 H NMR, 13 C NMR, and IR spectroscopic techniques. Compounds were screened for their in vitro antibacterial and antifungal activity against a variety of microorganisms namely, Bacillus subtilis, Enterococcus faecalis, Klebsiella pneumonia, Escherichia coli, Aspergillus fumigatus, Candida albicans , and Aspergillus clavatus . Quinazolinone linked p ‐hydroxyphenyl, o , p ‐dihydroxyphenyl and o ‐dimethylamino phenyl triazoles showed a remarkable antibacterial activity against E. faecalis with MIC values of 3.20±0.01, 4.01±0.04, and 4.10±0.01 μg mL −1 , and screened compounds p ‐nitrophenyl substituted triazole, and p ‐methylphenyl substituted triazole displayed a significant antifungal activity against C. albicans with MICs of 3.16±0.01, 4.06±0.03 μg mL −1 , compared to itraconazole (MIC=3.32±0.02 μg mL −1 ). For further exploration of the anti‐fungal mechanism of action, molecular docking was carried out for these compounds in C. albicans active site as one of the important antifungal inhibitors (PDB: 1A19). Furthermore, the ADMET profile was evaluated for all the final triazole compounds in contrast to reference drugs moxifloxacin and itraconazole. In conclusion, we discovered a novel quinazolinone linked 1,2,3‐triazoles with promising antimicrobial activity and a favorable pharmacokinetic profile.


  • Open Access

    Synthesis of Novel 2-Quinolone linked 1,2,3-Triazole Derivatives as Potent Antimicrobial Activities: in silico Docking Studies

    by Komal Chandrakar, Naveen Kumar Sureddy, S.P. Mahapatra, Santosh Penta

    The current research focuses on organic and medicinal chemistry, with a specific emphasis on the synthesis of molecules that incorporate diverse heterocycles. As part of this investigation, we have explored the fusion of 2-quinolone with 1,2,3-triazoles. Analytical and spectral data were applied to elucidate the structure of the synthesized compounds. In the preliminary antibacterial studies, analogs 4a, 4f, 6d and 6a were more effective against S. epidermidis corresponding MIC values of 6.32 ± 0.04, 2.38 ± 0.01, 5.18 ± 0.03 and 14.33 ± 0.01 µg/mL, respectively. In addition, compound 4a exhibited outstanding antibacterial activity against strains of Pseudomonas aeruginosa, as evidenced by a remarkable minimum inhibitory concentration (MIC) value of 3.19 ± 0.04 µg/mL. In particular, the synthesized scaffolds 6d, 4f, 4c and 4a showed significant antifungal activity with MIC values of 2.70 ± 0.01, 3.74 ± 0.03, 3.16 ± 0.02 and 4.18 ± 0.03 µg/mL against Candida albicans. The essential binding mode active site interactions in the DNA gyrase complex from Staphylococcus aureus based antibacterial drug candidate with 2XCO protein was also investigated and ligand 4a possesses the highest interacting amino acid residues ArgA:1092, PheA:1266, LysA:1043, AlaA:1172, AlaA:1034, TyrA:1099, HisA:1046, HisA:1046 [O11···NH], GlnA:1267 [O12···NE2], GlyA:1041 [N14···O, 3.22 Å], ThrA:1181 [O1···N]. The resulting scaffolds were assessed for ADMET and physico-chemical characteristics using ADMETlab2.0server, SwissADME web as good drugs with oral bioavailability.

  • Design, Synthesis, in Vitro, and in Silico Evaluations of 1,3,4‐Oxadiazole Derivatives Linked to the Pyrrolo[2,3‐ d ]pyrimidine Moieties as Potent Antimicrobial Targets

    by Jeevan Lal Patel, Naveen Kumar Sureddy, Murali Boddupalli, Raju Chedupaka, Venkatesham Papisetti, Mahapatra S. P., Santhosh Penta

    1,3,4‐Oxadiazole and its derivatives are well known assorted motif in drug design and development. The development of bacterial infection drug resistance serves as justification for the discovery of novel antimicrobial drugs. Thus, a novel series of 1,3,4‐oxadiazole derivatives linked to pyrrolo[2,3‐ d ]pyrimidine 6 a – f and 7 a – e was designed, synthesized and fully characterized by 1 H‐NMR, 13 C‐NMR, FT‐IR and mass spectroscopic analysis. All of the compounds′ in‐vitro antibacterial and antifungal activities were reported, and final oxadiazoles 6 d , 6 e , 6 f , and 7 e showed excellent antimicrobial inhibitory activity as compared to standard drugs. The compounds 6 f and 7 a exhibited potent antifungal activity as a potent inhibitor against C. albicans with MICs 4.0±0.03, 7.5±0.02 μg/mL respectively. In order to determine the different binding interactions that the most active oxadiazoles had with the Staphylococcus aureus DHFR enzyme, a docking study was conducted. The results indicated that the residues of amino acid Thr96(X), Leu62(X), Arg44(X), Asn18(X), Glu17(X), Lys45(X), Thr121(X), Gln95(X), Asp120(X), Ser64(X), Gly94(X), and Phe16(X) had promising energy value, within the range of −6.84 to −9.63 kcal/mol (PDB: 3FRA). The most effective inhibitors, 6 and 7 , also underwent in silico ADMET tests to predict their pharmacokinetic and physicochemical characteristics.


  • Synthesis of Benzimidazole Based 1,2,4‐Triazole Derivatives as Potential Anticancer Agents: In Silico Techniques

    by Komal Chandrakar, Naveen Kumar Sureddy, Raju Chedupaka, Venkatesham Papisetti, S. P. Mahapatra, Santhosh Penta

    Compounds with a 1,2,4–triazole scaffold serve an essential role in organic synthesis, particularly in the synthesis of bioactive organic compounds; thus, the development of new approaches for modifying this scaffold is a very interesting framework of this study. To contribute to the development of an efficient method for the conversion of anticancer triazoles, a novel series of benzimidazole based 1,2,4‐triazoles was designed and synthesized. All the newly synthesized derivatives were characterized by NMR ( 1 H & 13 C), FT–IR and mass spectrometry. Among the tested compounds, hybrids 5 b , 5 g exhibited exceptional anticancer susceptibilities with IC 50 =8.8±0.9, 9.2±1.5 μM against the tested HCA‐7cancer cell line. Anticancer profiles showed that compounds 5 d , 5 i had better anticancer inhibitory potency against a breast cancer cell line MCF‐7with IC 50 values 8.3±2.1, 10.6±1.2 μM, whereas 5 d , and 5 g showed potent anticancer activity against colorectal cancer cell line HT29 with IC 50 values 7.1±±0.9, 7.7±1.2 μM respectively. From docking results, 5 d demonstrated highly stable binding amino acids LeuA : 2247, GlyA : 2449, SerA : 2409, HisA : 2379, AspA : 2373, LysA : 2318, IleA : 2317, IleA : 2246, IleA : 2412, AlaA : 2410, GlnA : 2452, AsnA : 2245, TyrA : 2243, and HisA : 2448, which play a crucial role enabling optimal ligand binding in a crystal structure tyrosine phosphatase mutated in colorectal cancer (PDB: 1WCH). Furthermore, the physicochemical and absorption, distribution, metabolism, and excretion (ADME) filtration molecular properties, estimation of bioactivity, and toxicity scores of these scaffolds were evaluated.


  • Design, synthesis, molecular docking, and dynamic studies of novel thiazole derivatives incorporating benzimidazole moiety and assessment as antibacterial agents

    by Raju Chedupaka, Amrutha V. Audipudi, Akanksha Ashok Sangolkar, Srikanth Mamidala, Papisetti Venkatesham, Santhosh Penta, Rajeswar Rao Vedula

    A general and sustainable approach for the synthesis of benzimidazole-thiazole compounds via an efficient, one-pot, domino, pseudo-four-component reaction using 5-amino-2-mercaptobenzimidazole, aralkyl halides, ammonium thiocyanate, and substituted α-bromo-acetophenones in glacial acetic acid at ambient temperature to give final compounds (4a–p) in good yields in shorter time. The spectral data of synthesized compounds were evaluated by analytical and spectral techniques (IR, 1H-NMR, 13C-NMR, and ESI-HRMS). Further, some of the synthesized compounds were screened for their in-vitro antibacterial activity studies using the agar well diffusion method against Gram-positive Streptococcus pneumoniae (2451) bacteria and Gram-negative Proteous mirabilis (2081) bacteria. Based on the MIC results, it was observed that the most active compounds 4b, 4e, 4f, and 4k show promising antibacterial activity with the zone of inhibition values of 2.85 cm 2.75 cm, 3.6 cm, and 3.3 cm against both Gram-negative and positive bacteria cell lines, respectively. Further, we have also insight into the molecular simulation studies, based on the binding results, compound 4i showed stable binding interactions with streptomycin drug with the active site of the gyrase protein (PDB ID: 1KIJ). The structure–activity relationship (SAR) studies of all the title scaffolds were also established. The antibacterial activity, molecular docking studies, and molecular dynamic simulations of the title compounds suggested that these are promising antibacterial active skeletons. Graphical abstract

  • Efficient synthesis of novel 2-deoxy-C-nucleosides containing oxa and thiadiazole derivatives and their biological activity

    by Srishylam Penjarla, Paidi Yella Reddy, Santhosh Penta, Yogesh S. Sanghvi, Ludek Eyer, Michal Štefánik, Daniel Růžek, Shyamapada Banerjee